Author

Bernadett Farkas

USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY
USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

Bernadett Farkas  et al.

SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE
SHOTGUN ANALYSIS OF GUT MICROBIOTA WITH BODY COMPOSITION AND LIPID CHARACTERISTICS IN CROHN'S DISEASE

Bernadett Farkas  et al.

REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY
REAL-LIFE EFFECTIVENESS OF TOFACITINIB IN TWO INDICATIONS IN ULCERATIVE COLITIS: A RETROSPECTIVE WORLDWIDE, MULTICENTER, COLLABORATIVE STUDY

Bernadett Farkas  et al.

EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY
EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSE TREATMENT IS INDEPENDENT FROM DISEASE ACTIVITY AND DOES NOT REQUIRE THERAPY OPTIMISATION IN CASE OF SILENT IBD WITH IDA – A PROSPECTIVE STUDY

Bernadett Farkas  et al.

ACCURACY OF PANMAYO ENDOSCOPIC SCORE IN PREDICTING LONG-TERM DISEASE OUTCOMES IN ULCERATIVE COLITIS– A PROMISING SCORING SYSTEM
ACCURACY OF PANMAYO ENDOSCOPIC SCORE IN PREDICTING LONG-TERM DISEASE OUTCOMES IN ULCERATIVE COLITIS– A PROMISING SCORING SYSTEM

Bernadett Farkas  et al.

THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE
THE PREDICTIVE VALUE OF IRON DEFICIENCY ANAEMIA AND THE SEVERITY OF ANAEMIA ON THE ONE-YEAR DISEASE COURSE OF INFLAMMATORY BOWEL DISEASE

Bernadett Farkas  et al.

THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY
THE OUTCOMES OF PATIENTS TREATED WITH 2ND AND 3RD LINE BIOLOGICAL IN PERIANAL CROHN’S DISEASE (PCD) – A MULTICENTRE PROPENSITY SCORE MATCHED STUDY

Bernadett Farkas  et al.

Item 1 - 7 / 7
1